Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
Administration, Intranasal
Adult
Antibodies, Neutralizing
/ analysis
Antibodies, Viral
/ analysis
Female
Humans
Immunity, Mucosal
Immunoglobulin A, Secretory
/ analysis
Immunoglobulin G
/ blood
Influenza A Virus, H5N1 Subtype
Influenza Vaccines
/ administration & dosage
Influenza, Human
/ prevention & control
Male
Middle Aged
Nasal Mucosa
/ immunology
Vaccination
Vaccines, Inactivated
/ administration & dosage
Young Adult
HA-specific nasal IgA
immunological surrogates
inactivated whole-virion influenza vaccine
influenza A(H5N1) virus
intranasal inactivated influenza vaccine
Journal
Microbiology and immunology
ISSN: 1348-0421
Titre abrégé: Microbiol Immunol
Pays: Australia
ID NLM: 7703966
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
04
10
2019
revised:
08
01
2020
accepted:
17
01
2020
pubmed:
21
1
2020
medline:
21
10
2020
entrez:
21
1
2020
Statut:
ppublish
Résumé
Intranasally administered influenza vaccines could be more effective than injected vaccines, because intranasal vaccination can induce virus-specific immunoglobulin A (IgA) antibodies in the upper respiratory tract, which is the initial site of infection. In this study, immune responses elicited by an intranasal inactivated vaccine of influenza A(H5N1) virus were evaluated in healthy individuals naive for influenza A(H5N1) virus. Three doses of intranasal inactivated whole-virion H5 influenza vaccine induced strong neutralizing nasal IgA and serum IgG antibodies. In addition, a mucoadhesive excipient, carboxy vinyl polymer, had a notable impact on the induction of nasal IgA antibody responses but not on serum IgG antibody responses. The nasal hemagglutinin (HA)-specific IgA antibody responses clearly correlated with mucosal neutralizing antibody responses, indicating that measurement of nasal HA-specific IgA titers could be used as a surrogate for the mucosal antibody response. Furthermore, increased numbers of plasma cells and vaccine antigen-specific Th cells in the peripheral blood were observed after vaccination, suggesting that peripheral blood biomarkers may also be used to evaluate the intranasal vaccine-induced immune response. However, peripheral blood immune cell responses correlated with neutralizing antibody titers in serum samples but not in nasal wash samples. Thus, analysis of the peripheral blood immune response could be a surrogate for the systemic immune response to intranasal vaccination but not for the mucosal immune response. The current study suggests the clinical potential of intranasal inactivated vaccines against influenza A(H5N1) viruses and highlights the need to develop novel means to evaluate intranasal vaccine-induced mucosal immune responses.
Identifiants
pubmed: 31957054
doi: 10.1111/1348-0421.12775
pmc: PMC7216874
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin A, Secretory
0
Immunoglobulin G
0
Influenza Vaccines
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
313-325Subventions
Organisme : Grant-in-Aid for Research on Emerging and Reemerging Infectious Diseases from the Japanese Ministry of Health, Labor, and Welfare (MHLW)
ID : H25-Shinkou-Ippan-018
Organisme : Grant-in-Aid for Research on Emerging and Reemerging Infectious Diseases from the Japan Agency for Medical Research and Development (AMED)
ID : JP18fk0108012
Organisme : Grant-in-Aid for Research on Emerging and Reemerging Infectious Diseases from the Japan Agency for Medical Research and Development (AMED)
ID : JP19fk0108051
Organisme : Grant-in-Aid for Research on Emerging and Reemerging Infectious Diseases from the Japan Agency for Medical Research and Development (AMED)
ID : JP19fk0108082
Organisme : Grant-in-Aid for Research on Emerging and Reemerging Infectious Diseases from the Japan Agency for Medical Research and Development (AMED)
ID : JP19fk0108083
Informations de copyright
© 2020 The Authors. Microbiology and Immunology published by The Societies and John Wiley & Sons Australia, Ltd.
Références
Microbiol Immunol. 2020 Apr;64(4):313-325
pubmed: 31957054
Expert Rev Vaccines. 2018 Aug;17(8):687-696
pubmed: 30092690
Clin Infect Dis. 2004 Apr 1;38(7):974-80
pubmed: 15034829
Microbes Infect. 2007 Sep;9(11):1333-40
pubmed: 17890128
Front Immunol. 2012 Apr 17;3:78
pubmed: 22566959
J Infect Chemother. 2017 Sep;23(9):615-620
pubmed: 28668446
J Infect Dis. 2007 Dec 1;196(11):1671-8
pubmed: 18008252
Vaccine. 2016 Feb 24;34(9):1201-7
pubmed: 26802605
Clin Microbiol Rev. 2013 Jul;26(3):476-92
pubmed: 23824369
Hum Vaccin Immunother. 2018 Jun 3;14(6):1351-1361
pubmed: 29425074
Vaccine. 2003 Jun 2;21(19-20):2362-71
pubmed: 12744867
J Immunol. 2004 Aug 1;173(3):1978-86
pubmed: 15265932
Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7809-14
pubmed: 26056267
EMBO Mol Med. 2018 Mar;10(3):
pubmed: 29363490
J Lab Clin Med. 1964 Jan;63:5-13
pubmed: 14102904
N Engl J Med. 2004 Feb 26;350(9):896-903
pubmed: 14985487
Vaccine. 2017 Sep 25;35(40):5388-5395
pubmed: 28866292
Hum Vaccin Immunother. 2013 Sep;9(9):1962-70
pubmed: 23896606
J Med Virol. 2012 Feb;84(2):336-44
pubmed: 22170556
Hum Vaccin. 2010 Oct;6(10):792-801
pubmed: 20935469
N Engl J Med. 2017 Aug 10;377(6):534-543
pubmed: 28792867
Curr Top Microbiol Immunol. 1989;146:107-16
pubmed: 2659262
N Engl J Med. 2006 Mar 30;354(13):1343-51
pubmed: 16571878
J Biol Stand. 1980;8(3):233-42
pubmed: 7410447